Sanofi Says BARDA Wants It to `Go On' With Covid Shots

The transcript covers Sanofi's financial performance, pipeline development, and COVID-19 vaccine efforts. It highlights the company's strong EPS growth and successful pipeline management despite the pandemic. Sanofi is working on two COVID-19 vaccine candidates and contributing to the production of existing vaccines. The discussion also addresses the potential over-reliance on Dupixent and the development of other promising drugs.

What challenges does Sanofi face in the production of COVID vaccines?

How does Dupixent fit into Sanofi's overall business strategy?

What are the potential future developments for Sanofi's pipeline?